clinical trial · NCT07449390
Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole
Acesion Pharma·phase1·recruiting·n = 28
Healthy ParticipantsAP31969CarbamazepineItraconazole
brief summary
The primary objective of the trial is to assess the effect of multiple doses of the cytochrome P450 (CYP3A4) enzyme inducer carbamazepine (Part A) or the CYP3A4 inhibitor itraconazole (Part B) on the single-dose pharmacokinetics (PK) of AP31969 in healthy participants.
started
Apr 1, 2026
primary completion
May 16, 2026
completion
May 16, 2026
last updated
Apr 23, 2026
official title
Open-label, 2-Part, Fixed-sequence, Crossover Trial Design to Determine the Effect of a Strong CYP3A4 Inducer (Carbamazepine) And a Strong CYP3A4 Inhibitor (Itraconazole) on the Pharmacokinetics of a Single Oral Dose of AP31969 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol